Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal

E Windler; B-Chr Zyriax

doi:10.1016/j.atherosclerosissup.2015.02.027

Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal

Standard

Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. / Windler, E; Zyriax, B-Chr.

in: ATHEROSCLEROSIS PLUS, Jahrgang 18, 05.2015, S. 176-179.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Windler, E & Zyriax, B-C 2015, 'Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal', ATHEROSCLEROSIS PLUS, Jg. 18, S. 176-179. https://doi.org/10.1016/j.atherosclerosissup.2015.02.027

APA

Windler, E., & Zyriax, B-C. (2015). Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. ATHEROSCLEROSIS PLUS, 18, 176-179. https://doi.org/10.1016/j.atherosclerosissup.2015.02.027

Vancouver

Windler E, Zyriax B-C. Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. ATHEROSCLEROSIS PLUS. 2015 Mai;18:176-179. https://doi.org/10.1016/j.atherosclerosissup.2015.02.027

Bibtex

@article{280a319296e24c2681d95f938e980783,

title = "Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal",

abstract = "Current guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS), of the American College of Cardiology and the American Heart Association (ACC/AHA), and of the International Atherosclerosis Society (IAS) are all based on the same body of evidence, but come to strikingly different conclusions with regard to lipid lowering therapy. While the ESC/EAS guidelines assign appropriate treatments to distinct lipid disorders, the ACC/AHA guidelines focus exclusively on evidence from randomized controlled trials for statins, but lack advice for those lipid disorders without evidence from randomized trials. Thus, evidence based medicine in its strict sense may leave a clinically significant gap. In striking contrast, the position paper of the IAS suggests the most advanced evidence-based innovative concept of a goal of one and the same healthy cholesterol level for anyone. ",

keywords = "Anticholesteremic Agents/therapeutic use, Biomarkers/blood, Cholesterol, LDL/blood, Down-Regulation, Evidence-Based Medicine/standards, Guideline Adherence/standards, Humans, Hypercholesterolemia/blood, Practice Guidelines as Topic/standards, Risk Factors, Risk Reduction Behavior, Treatment Outcome",

author = "E Windler and B-Chr Zyriax",

year = "2015",

month = may,

doi = "10.1016/j.atherosclerosissup.2015.02.027",

language = "English",

volume = "18",

pages = "176--179",

journal = "ATHEROSCLEROSIS PLUS",

issn = "2667-0895",

publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal

AU - Windler, E

AU - Zyriax, B-Chr

PY - 2015/5

Y1 - 2015/5

N2 - Current guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS), of the American College of Cardiology and the American Heart Association (ACC/AHA), and of the International Atherosclerosis Society (IAS) are all based on the same body of evidence, but come to strikingly different conclusions with regard to lipid lowering therapy. While the ESC/EAS guidelines assign appropriate treatments to distinct lipid disorders, the ACC/AHA guidelines focus exclusively on evidence from randomized controlled trials for statins, but lack advice for those lipid disorders without evidence from randomized trials. Thus, evidence based medicine in its strict sense may leave a clinically significant gap. In striking contrast, the position paper of the IAS suggests the most advanced evidence-based innovative concept of a goal of one and the same healthy cholesterol level for anyone.

AB - Current guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS), of the American College of Cardiology and the American Heart Association (ACC/AHA), and of the International Atherosclerosis Society (IAS) are all based on the same body of evidence, but come to strikingly different conclusions with regard to lipid lowering therapy. While the ESC/EAS guidelines assign appropriate treatments to distinct lipid disorders, the ACC/AHA guidelines focus exclusively on evidence from randomized controlled trials for statins, but lack advice for those lipid disorders without evidence from randomized trials. Thus, evidence based medicine in its strict sense may leave a clinically significant gap. In striking contrast, the position paper of the IAS suggests the most advanced evidence-based innovative concept of a goal of one and the same healthy cholesterol level for anyone.

KW - Anticholesteremic Agents/therapeutic use

KW - Biomarkers/blood

KW - Cholesterol, LDL/blood

KW - Down-Regulation

KW - Evidence-Based Medicine/standards

KW - Guideline Adherence/standards

KW - Humans

KW - Hypercholesterolemia/blood

KW - Practice Guidelines as Topic/standards

KW - Risk Factors

KW - Risk Reduction Behavior

KW - Treatment Outcome

U2 - 10.1016/j.atherosclerosissup.2015.02.027

DO - 10.1016/j.atherosclerosissup.2015.02.027

M3 - SCORING: Review article

C2 - 25936323

VL - 18

SP - 176

EP - 179

JO - ATHEROSCLEROSIS PLUS

JF - ATHEROSCLEROSIS PLUS

SN - 2667-0895

ER -